Buy Immupharma (IMM) says VectorVest. This pharma stock still offers further upside for the adventurous investor.

AIM listed ImmuPharma (IMM.L) is a drug discovery and development company. The London-based Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. IMM has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company’s drug candidate and is a treatment for lupus, and life threatening auto immune disease. IMM’s cancer treatment, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company’s research operations are in France.

FREE! For free VectorVest analysis on any stock, go to this link here

On September 27^th 2017, IMM reported interim results, recording a reduced interim loss of £3m for the half year to June 30. Following a successful £4.1m fundraising in March 2017, IMM now has net assets of £6.4m, up from £5.5m at 31 Dec 2016. The company said that all patients in its Lupuzor study had “now passed the six months stage, with over 26% of patients having now completed the full 12 months.” Subject to approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), Immupharma is now planning ahead in anticipation of the trial’s successful outcome and expects to have the first set of batches ready by the end of Q1 2018. IMM sees a number of routes to market for Lupuzor, which could include a global licensing deal.

Although the IMM share price exploded higher in late September, VectorVest stock graph analysis logged growth in the GRT (Earnings Growth Rate) in mid June, when the shares were trading around 50p. Despite climbing to 93p, IMM still retains a forecasted GRT of 33%, which VectorVest considers to be excellent. Traders should note that the RS (Relative Safety) metric records a fair rating of 0.90 on a scale of 0.00 to 2.00, but with a current VectorVest valuation of 120p per share, in the run up to commercialisation of Lupuzor, IMM shares remain undervalued.

The chart of IMM is shown above in my normal format. Earnings per share (EPS) are shown in the window below the price. The rapid rise of EPS in July 2017 and the resultant revaluation of IMM.L gave 2 ½ months warning of the breakout in price. Remember EPS growth is the engine that drives the share price. From the 2^nd to the 6^th of October 2017 the advance in price consolidated prior to a break upwards on the 9^th October 2017. The probabilities favour this to continue to the VectorVest valuation.

Summary: From time to time the pharmaceutical sector can provide stellar returns, as small pharma companies either bring a groundbreaking drug to market or are acquired by global drug giants. IMM looks to be close to completing the former with Lupuzor, and with a number of other drug candidates in development and a raft of patents, the stock does still appear to offer further upside for the adventurous investor. Speculative buy.

Dr David Paul

October 10th 2017

Readers can examine trading opportunities on IMM and a host of other similar stocks for a single payment of £5.95. This gives access to the VectorVest Risk Free 5-week trial, where members enjoy unlimited access to VectorVest UK & U.S., plus VectorVest University for on-demand strategies and training. Link here to view.

VectorVest Unisearch

On VectorVest a simple search using the Unisearch tool will quickly find shares that are undervalued with good fundamentals that have just issued a Buy recommendation. This will give the active trader a short list of many high probability trading opportunities each week. Traders now have the opportunity to spend five weeks discovering VectorVest’s unique simplicity, automation and independent guidance. Just £5.95 buys a 5 week trial to enable deep exploration, or how the system can assist in smarter trading in as little as 10 minutes a day. Powerful tools. Proven strategies. Unique Perspectives.

Link here for more info and to set up a trial. 

European Financial Publishing Limited T/A VectorVest UK (VectorVest) is authorised and regulated by the Financial Conduct Authority under register number 543038. You should remember that the value of investments and the income derived therefrom may fall as well as rise and you may not get back the amount that you invest. Past performance is not a reliable guide to the future. This material is directed only at persons in the UK and is not an offer or invitation to buy or sell securities. If investors are in any doubt of the suitability of an investment given their individual circumstances, they are recommended to contact an investment manager or independent financial adviser who may be able to provide tailored advice. Opinions expressed whether in general or both on the performance of individual securities and in a wider economic context represent the views of VectorVest at the time of preparation. They are subject to change and should not be interpreted as investment advice. VectorVest and connected companies, clients, directors, employees and other associates, may have a position in any security, or related financial instrument, issued by a company or organisation mentioned on this site. European Financial Publishing Limited is a company incorporated in Scotland under Company Number SC357322 with its registered address at Exchange Tower, 19 Canning Street, Edinburgh EH3 8EH. Email: support@VectorVest.com